FrancophonIA/ELRC3.0 huggingface dataset:
English: Do not take Namuscla - if you are allergic to mexiletine or to any of the other ingredients of this medicine (listed in section 6) - if you are allergic to any local anaesthetic - if you have had heart attack - if your heart does not work well enough - if you have certain disorders of the heart rhythm - if your heart beats too fast - if the blood vessels of your heart are damaged - if you also take certain medicines to treat disorders of the heart rhythm (see Other medicines and Namuscla) - if you also take certain medicines which have a narrow therapeutic window (see Other medicines and Namuscla).
Croatian: Nemojte uzimati lijek Namuscla - ako ste alergični na meksiletin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) - ako ste alergični na bilo koji lokalni anestetik - ako ste imali srčani udar - ako Vaše srce ne radi dovoljno dobro - ako imate određene poremećaje srčanog ritma - ako Vaše srce kuca prebrzo - ako su krvne žile Vašeg srca oštećene - ako uzimate i određene lijekove za liječenje poremećaja srčanog ritma (pogledajte dio Drugi lijekovi i Namuscla) - ako uzimate i određene lijekove koji imaju usku terapijsku širinu (pogledajte dio Drugi lijekovi i Namuscla)
English: If mexiletine and other OCT2 substrates are to be used concurrently, the OCT2 substrate blood levels should be monitored, particularly when the mexiletine dose is changed.
Croatian: Ako se meksiletin i drugi supstrati OCT2 primjenjuju istodobno, treba nadzirati razine supstrata OCT2 u krvi, osobito kod promjene doze meksiletina.
English: The symptoms of mexiletine overdose include neurological disorders (paresthesia, confusion, hallucination, seizure) and cardiac disorders (sinusal bradycardia, hypotension, collapse, and in extreme cases, cardiac arrest).
Croatian: Simptomi predoziranja meksiletinom uključuju neurološke poremećaje (paresteziju, konfuziju, halucinacije, napadaje) i srčane poremećaje (sinusnu bradikardiju, hipotenziju, kolaps, a u ekstremnim slučajevima i srčani arest).
English: What Namuscla is and what it is used for
Croatian: Što je Namuscla i za što se koristi
English: Median value at Day 18
Croatian: Medijan 18. dan
English: Electrolyte imbalance needs to be corrected before administering mexiletine and to be monitored throughout treatment (with a periodicity to be adapted patient by patient).
Croatian: Neravnotežu elektrolita treba ispraviti prije primjene meksiletina i pratiti tijekom cijelog liječenja (s učestalošću koja se prilagođava za svakog pojedinog bolesnika).
English: A period of at least 7 days before dose increase must be respected to ensure that steady-state levels are reached, irrespective of the patient's CYP450 polymorphism.
Croatian: Mora se poštovati razdoblje od najmanje 7 dana prije povećanja doze kako bi se osiguralo postizanje stabilnih razina, bez obzira na polimorfizam CYP450 u bolesnika.
English: The CYP1A2 substrate blood levels should be monitored, particularly when the mexiletine dose is changed.
Croatian: Treba nadzirati razine supstrata CYP1A2 u krvi, osobito kod promjene doze meksiletina.
English: Weight In population pharmacokinetic analyses, weight was found to influence mexiletine pharmacokinetics.
Croatian: U analizama populacijske farmakokinetike, pokazalo se da tjelesna težina utječe na farmakokinetiku.
English: The potential of mexiletine as a drug-drug-interaction perpetrator is unknown.
Croatian: Potencijal meksiletina da uzrokuje interakcije između lijekova nije poznat.
English: interval (≥ 240 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block,
Croatian: PR intervalom (≥ 240 ms) i/ili širokim QRS kompleksom (≥ 120 ms), atrioventrikularni blok drugog stupnja, blok grane snopa, bifascikularni ili trifascikularni blok)
English: Mexiletine should be stopped immediately in case any cardiac conduction abnormalities or any of the contraindications listed in the section 4.3 are detected.
Croatian: Primjenu meksiletina treba odmah prekinuti u slučaju anomalija provodljivosti srca ili otkrivanja bilo koje kontraindikacije navedene u dijelu 4.3.
English: • Contraindications with Namuscla which may increase the susceptibility to arrhythmias;
Croatian: • Kontraindikacije s lijekom Namuscla koje mogu povećati osjetljivost na aritmije;
English: • Namuscla should be stopped immediately if the patient develops cardiac abnormalities, is not responding or experiencing benefit within Namuscla long-term treatment;
Croatian: • Namuscla se mora odmah prestati davati ako bolesnik razvije srčane abnormalnosti ili ako nema odgovora ili poboljšanja nakon dugotrajnog liječenjem lijekom Namuscla.
English: Up to 5%
Croatian: Do 5 %
English: Mexiletine dose may need to be increased if a patient starts to smoke during mexiletine treatment and decreased if a patient stops smoking.
Croatian: Dozu meksiletina možda će trebati povećati ako bolesnik počne pušiti tijekom liječenja meksiletinom, a smanjiti ako bolesnik prekine s pušenjem.
English: In a clinical study, co-administration of mexiletine with phenytoin resulted in a significant decrease in exposure to mexiletine (p < 0.003) due to enhanced clearance as reflected in significantly decreased elimination half-life (17.2 to 8.4 hours, p < 0.02).
Croatian: U kliničkom ispitivanju, istodobna primjena meksiletina i fenitoina uzrokovala je značajno smanjenu izloženost meksiletinu (p < 0,003) zbog višeg klirensa, što se odrazilo u značajno kraćem poluvijeku eliminacije (17,2 do 8,4 sata, p < 0,02).
English: Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with nondystrophic myotonic disorders.
Croatian: Namuscla je indicirana za simptomatsko liječenje miotonije u odraslih bolesnika s nedistrofičnim poremećajima miotonije.
English: Other antiarrhythmics (class Ib, II, IV antiarrhythmics):
Croatian: Ostali antiaritmici (antiaritmici skupine Ib, II, IV):
English: Musculoskeletal and connective tissue disorders Common: pain in the extremities
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva Često: bol u ekstremitetima
English: An appropriate adjustment in the dose of the CYP1A2 substrate should be considered.
Croatian: Treba razmotriti odgovarajuću prilagodbu doze supstrata CYP1A2.
English: Very common side effects (may affect more than 1 in 10 people): - Abdominal (belly) pain - Insomnia (difficulty sleeping)
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba): - bol u abdomenu (trbuhu) - nesanica (otežano spavanje)
English: Higher systemic exposure is expected in patients who are CYP2D6 poor metabolisers or who take medicinal products that inhibit CYP2D6 (see section 4.5).
Croatian: Očekuje se viša sistemska izloženost u bolesnika sa sporim metabolizmom CYP2D6 ili onih koji uzimaju lijekove koji inhibiraju djelovanje CYP2D6 (vidjeti dio 4.5).
English: If you become pregnant while taking Namuscla, see your doctor immediately.
Croatian: Ako zatrudnite tijekom uzimanja lijeka Namuscla, odmah se javite liječniku.
English: Cardiac arrhythmogenic effects
Croatian: Kardijalni aritmogeni učinci
English: • Highlight the risk of decreased Namuscla clearance in patients with hepatic impairment and provide guidance on how to treat those patients in order to prevent it, ensuring Namuscla cautious titration in patients with mild or moderate hepatic impairment (increasing the dose after at least 2 weeks of treatment).
Croatian: • Istaknuti rizik od smanjenja klirensa lijeka Namuscla u bolesnika s oštećenjem jetre i dati upute o tome kako liječiti takve bolesnike kako bi se to spriječilo, osiguralo opreznu titraciju u bolesnika s blagim ili umjerenim oštećenjem jetre (povećanjem doze nakon barem 2 tjedna liječenja).
English: Talk to your doctor or pharmacist or nurse before taking Namuscla if you have: - heart problems
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete lijek Namuscla ako imate:
English: Common: somnolence
Croatian: Često: somnolencija
English: • Patient alert card
Croatian: • Karticu upozorenja za bolesnika
English: The most serious reported adverse reactions in patients treated with mexiletine are drug reaction with eosinophilia and systemic symptoms and arrhythmia (atrioventricular block, arrhythmia, ventricular fibrillation).
Croatian: Najozbiljnije prijavljene nuspojave u bolesnika liječenih meksiletinom su reakcija na lijek s eozinofilijom i sistemskim simptomima te aritmija (atrioventrikularni blok, aritmija, fibrilacija klijetki).
English: Several of the resulting metabolites are submitted to further conjugation with glucuronic acid (phase II metabolism); among these are the major metabolites p-hydroxymexiletine, hydroxy-methylmexiletine and N-hydroxymexiletine.
Croatian: Nekoliko rezultirajućih metabolita podvrgava se daljnjoj konjugaciji s glukuronskom kiselinom (metabolizam II. faze); tu spadaju glavni metaboliti p-hidroksimeksiletin, hidroksimetilmeksiletin i N-hidroksimeksiletin.
English: Examples of such medicines are digoxin (for heart problems), lithium (mood stabiliser), phenytoin (for treating epilepsy), theophylline (against asthma) and warfarin (against blood clots).
Croatian: Primjeri takvih lijekova su digoksin (za probleme sa srcem), litij (stabilizator raspoloženja), fenitoin (za liječenje epilepsije), teofilin (protiv astme) i varfarin (protiv zgrušavanja krvi).
English: • Information about symptoms of cardiac arrhythmias, which can be life-threatening, and when patients should seek HCP attention;
Croatian: • Podaci o simptomima srčanih aritmija koje mogu biti opasne po život i kada bolesnici moraju potražiti medicinsku pomoć;
English: The influence of CYP2D6 phenotype on mexiletine metabolism has been extensively investigated.
Croatian: Utjecaj fenotipa CYP2D6 na metabolizam meksiletina opsežno je proučen.
English: The concomitant use of mexiletine and antiarrhythmic medicines inducing torsades de pointes is contraindicated (see section 4.3).
Croatian: Istodobna primjena meksiletina i antiaritmičnih lijekova koji izazivaju torsades de pointes je kontraindicirana (vidjeti dio 4.3).
English: Smoking affects mexiletine pharmacokinetics (see section 4.5).
Croatian: Pušenje utječe na farmakokinetiku meksiletina (vidjeti dio 4.5).
English: • Patients should carry the card at all times, and show it at all medical visits to HCPs other than the prescriber (e.g. emergency HCPs);
Croatian: • Bolesnici moraju nositi karticu cijelo vrijeme sa sobom i pokazati je prilikom svih posjeta zdravstvenom radniku koji nije liječnik koji je propisao lijek (npr. osoblje u hitnoj medicinskoj pomoći);
English: Clinical Myotonia Scale - Disability Global Score Number of subjects
Croatian: Ljestvica kliničke miotonije - globalni rezultat invalidnosti Broj ispitanika
English: Patients should be informed about the presenting symptoms of arrhythmias (fainting, palpitation, chest pain, shortness of breath, light-headedness, lipothymia, and syncope) and should be advised to immediately contact an emergency centre if there are any symptoms of arrhythmias.
Croatian: Bolesnike treba informirati o nastupu simptoma aritmija (nesvjestica, palpitacije, bol u prsištu, nedostatak zraka, ošamućenost, lipotimija i sinkopa) i treba im savjetovati da se odmah jave u hitnu medicinsku službu u slučaju bilo kakvih simptoma aritmija.
English: An appropriate adjustment in the dose of the OCT2 substrate should be considered.
Croatian: Treba razmotriti odgovarajuću prilagodbu doze supstrata OCT2.
English: Mexiletine is, therefore, mostly active on muscle fibres subject to repeated discharges (such as skeletal muscles).
Croatian: Meksiletin je stoga najaktivniji na mišićnim vlaknima koja se učestalo aktiviraju (poput skeletnih mišića).
English: In order to prevent and / or minimise the important identified risks of Cardiac Arrhythmia in patients with Dystrophic Myotonia (off-label use) and Decreased Namuscla clearance, thus the risk of adverse reactions in patients with hepatic impairment, the MAH shall ensure that in each MS where Namuscla is marketed, all healthcare professionals (HCPs) and patients are provided, respectively, with:
Croatian: U svrhu sprječavanja i/ili minimiziranja važnih identificiranih rizika od srčane aritmije u bolesnika s distrofičnom miotonijom (primjena lijeka izvan indikacije) i smanjenog klirensa lijeka Namuscla i time rizika od nuspojava u bolesnika s oštećenjem jetre, nositelj odobrenja za stavljanje lijeka u promet dužan je osigurati da u svakoj državi članici u kojoj je lijek Namuscla odobren svi zdravstveni radnici i bolesnici dobiju:
English: The potential interactions between mexiletine and substrates of other common enzymes and transporters have not yet been assessed; it is currently contra-indicated to use mexiletine with any substrate having a narrow therapeutic window such as digoxin, lithium, phenytoin, theophylline or warfarin (see section 4.3).
Croatian: Potencijalne interakcije između meksiletina i supstrata drugih uobičajenih enzima i transportera još nisu procijenjene; trenutno je kontraindicirana primjena meksiletina s bilo kojim supstratom s uskim terapijskim indeksom poput digoksina, litija, fenitoina, teofilina ili varfarina (vidjeti dio 4.3).
English: • Educational guide for HCPs;
Croatian: • Vodič za edukaciju za zdravstvene radnike;
English: These tests will also be performed regularly during treatment with Namuscla, and before and after your dose of Namuscla is modified.
Croatian: Te pretrage također ćete redovito obavljati tijekom liječenja lijekom Namuscla i prije i nakon promjene vaše doze.
English: Very rare side effects (may affect up to 1 in 10,000 people): - Liver injury including inflammation (hepatitis) - Severe reaction to the medicine (with rash and fever)
Croatian: Vrlo rijetke nuspojave (mogu se javiti u do 1 na 10 000 osoba): - oštećenje jetre uključujući upalu (hepatitis) - teška reakcija na lijek (s osipom i visokom temperaturom)
English: Check of heart function
Croatian: Provjera srčane funkcije
English: Namuscla may in rare cases cause tiredness, confusion, blurred vision: If you have these effects do not drive, cycle and use machines.
Croatian: Namuscla može u rijetkim slučajevima uzrokovati umor, smetenost, zamućen vid: nemojte upravljati vozilom, voziti bicikl ni koristiti strojeve ako osjećate te učinke.
English: Food does not affect the rate or extent of absorption of mexiletine.
Croatian: Hrana ne utječe na stopu ni na opseg apsorpcije meksiletina.
English: • HCPs should counsel patients on: o The risk of cardiac arrhythmias (informing about symptoms of arrhythmias, advising patients to contact immediately their HCP, or emergency centres, if they experience any of these symptoms);
Croatian: • Zdravstveni radnici moraju savjetovati bolesnike o: o Rizicima od srčanih aritmija (informirajući ih o simptomima aritmija, savjetujući bolesnike da odmah kontaktiraju svog liječnika ili centar hitne medicinske pomoći ako iskuse neke od tih simptoma);
English: Throughout treatment with mexiletine, and in relation with dose changes, cardiac monitoring of patients needs to be adapted as a function of the heart condition of the patient:
Croatian: Tijekom cijelog liječenja meksiletinom i vezano uz izmjene doze, treba prilagoditi kardijalno praćenje bolesnika prema stanju srca bolesnika:
English: Common side effects (may affect up to 1 in 10 people): - Somnolence (sleepiness) - Headache - Tingling in the arms and legs - Blurred vision - Vertigo (sensation of feeling off balance) - Rapid heart rate - Flushing - Low blood pressure (which can cause dizziness and feeling faint) - Nausea (feeling sick) - Acne - Pain in the arms and legs - Tiredness - Weakness - Chest discomfort - Malaise (a feeling of general discomfort and illness)
Croatian: Česte nuspojave (mogu se javiti u do 1 na 10 osoba): - pospanost - glavobolja - trnci u rukama i nogama - zamućen vid - vrtoglavica (osjećaj gubitka ravnoteže) - ubrzan rad srca - navale crvenila - snižen krvni tlak (koji može uzrokovati omaglicu i osjećaj slabosti) - mučnina - akne - bol u rukama i nogama - umor - slabost - osjećaj nelagode u prsnom košu - malaksalost (osjećaj opće neugode i bolesti)
English: • Patients should inform the HCP about any ongoing medications or before starting any new medication, while on treatment with Namuscla;
Croatian: • Bolesnici moraju obavijestiti zdravstvenog radnika o svim lijekovima koje uzimaju ili prije početka uzimanja bilo kojih drugih lijekova tijekom liječenja lijekom Namuscla;
English: Animal studies with mexiletine do not indicate harmful effects with respect to fertility (see section 5.3).
Croatian: Ispitivanja meksiletina na životinjama ne ukazuju na štetne učinke na plodnost (vidjeti dio 5.3).
English: • Inform patients that, before starting and throughout treatment with Namuscla, HCPs should perform a detailed and careful cardiac evaluation;
Croatian: • Obavijestiti bolesnike da prije početka i tijekom cjelokupnog liječenja lijekom Namuscla liječnik mora provoditi detaljnu i pažljivu kardijalnu procjenu;
English: The Educational guide for HCPs, which should always be read in conjunction with the Summary of Product Characteristics (SmPC) before prescribing Namuscla, should contain the following key elements:
Croatian: Vodič za edukaciju za zdravstvene radnike, kojeg uvijek treba čitati zajedno sa sažetkom opisa svojstava lijeka prije propisivanja lijeka Namuscla, mora sadržavati sljedeće ključne elemente:
English: Before starting mexiletine treatment, detailed and careful cardiac evaluation should be carried out; throughout treatment with mexiletine, cardiac monitoring needs to be continued and adapted as a function of the heart condition of the patient (see contraindications in section 4.3 and warning in section 4.4).
Croatian: Prije početka liječenja meksiletinom, potrebno je provesti detaljni kardiološki pregled, a tijekom cjelokupnog liječenja meksiletinom potrebno je nastaviti kardiološki nadzor i prilagoditi ga stanju srca bolesnika (vidjeti kontraindikacije u dijelu 4.3 i upozorenje u dijelu 4.4).
English: Very common: abdominal pain
Croatian: Vrlo često: bol u abdomenu
English: If you become pregnant while taking Namuscla, see your doctor immediately as it is preferable not to take Namuscla while you are pregnant.
Croatian: Ako zatrudnite tijekom uzimanja lijeka Namuscla, odmah se javite liječniku, jer se preporuča ne uzimati lijek Namuscla tijekom trudnoće.
English: In a single-dose interaction study, the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.
Croatian: U ispitivanju interakcije s jednom dozom, klirens meksiletina smanjen je za 38 % nakon istodobne primjene fluvoksamina, inhibitora CYP1A2.
English: Therefore, electrolytic evaluation should be done prior to initiating therapy with mexiletine in every patient.
Croatian: Zato procjenu elektrolita za svakog bolesnika treba obaviti prije početka terapije meksiletinom.
English: Patients with cardiac disorders
Croatian: Bolesnici s poremećajima srčane funkcije
English: Very common: insomnia
Croatian: Vrlo često: nesanica
English: If you have any doubt, ask your doctor or pharmacist.
Croatian: Ako imate ikakvu sumnju, upitajte svojeg liječnika ili ljekarnika.
English: What you need to know before you take Namuscla
Croatian: Što morate znati prije nego počnete uzimati lijek Namuscla
English: Not known: circulatory collapse, hot flush Respiratory, thoracic and mediastinal disorders Not known: pulmonary fibrosis
Croatian: Nepoznato: cirkulatorni kolaps, navala vrućine Poremećaji dišnog sustava, prsišta i sredoprsja Nepoznato: fibroza pluća
English: • Before starting treatment, HCPs should perform a detailed and careful cardiac evaluation in all patients, in order to determine the cardiac tolerability of Namuscla.
Croatian: • Prije početka liječenja, zdravstveni radnik mora provesti detaljnu i pažljivu kardijalnu procjenu kod svih bolesnika kako bi odredio toleranciju srca na lijek Namuscla.
English: Namuscla should not be used in patients with severe hepatic impairment;
Croatian: Namuscla se ne smije primjenjivati u bolesnika s teškim oštećenjem jetre;
English: Contact your doctor or go to your nearest emergency center immediately if you experience any of the following side effects: - severe allergy to mexiletine (with symptoms such as severe rash with fever); this is a very rare side effect, may affect up to 1 in 10,000 people.
Croatian: Odmah kontaktirajte svog liječnika ili odite u najbližu službu hitne pomoći ako iskusite bilo koju od sljedećih nuspojava: - teška alergija na meksiletin (sa simptomima poput jakog osipa uz visoku temperaturu); ovo je jako rijetka nuspojava koja se može pojaviti kod 1 od 10 000 osoba. - poremećaji srčanog ritma, pogledajte dio „Upozorenja i mjere opreza“ za simptome i dodatne informacije; ovo je česta nuspojava koja se može pojaviti kod 1 od 10 osoba.
English: What Namuscla contains
Croatian: Što Namuscla sadrži
English: Not known (frequency cannot be estimated from the available data): - Decrease in white blood cells or in platelets - Lupus syndrome (disease of the immune system) - Redness and peeling of the skin - Stevens-Johnson syndrome: a severe allergic reaction with skin rashes, often in the form of blisters and sores in the mouth and eyes, and other mucous membranes - Blisters of the skin, malaise and fever in the context of a condition called DRESS - Hallucinations (seeing or hearing something that is not present).
Croatian: Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka): - smanjen broj bijelih krvnih zrnaca ili krvnih pločica - sindrom lupusa (bolest imunološkog sustava) - crvenilo i ljuštenje kože - Stevens-Johnsonov sindrom: teška alergijska reakcija s osipom kože, često u obliku mjehura ili rana u ustima i očima i na ostalim sluznicama - plikovi na koži, malaksalost i vrućica u kontekstu stanja koji se naziva DRESS - halucinacije (viđenje ili slušanje nepostojećeg) - prolazna smetenost (privremena nesposobnost bistrog razmišljanja ili koncentracije) - dvoslika - izmijenjen osjet okusa - poremećaji srčanog ritma - kolaps
English: Rare side effects (may affect up to 1 in 1,000 people): - Abnormal functioning of the liver (observed after blood analysis).
Croatian: Rijetke nuspojave (mogu se javiti u do 1 na 1000 osoba): - poremećen rad jetre (zapažen nakon pretraga krvi).
English: How to store Namuscla 6.
Croatian: Kako čuvati lijek Namuscla 6.
English: A period of at least 7 days before dose increase must be respected to ensure that steady-state levels are reached and that mexiletine is well tolerated in all patients, irrespective of CYP450 polymorphism.
Croatian: Razdoblje od najmanje 7 dana prije povećanja doze mora se poštivati, kako bi se osiguralo postizanje stanja dinamičke ravnoteže i dobra podnošljivost meksiletina kod svih bolesnika, neovisno o polimorfizmu CYP450.
English: • In patients without cardiac abnormalities, periodic ECG monitoring is recommended (every 2 years or more frequently if considered necessary).
Croatian: • U bolesnika bez srčanih anomalija, preporuča se obaviti redovito EKG praćenje (svake 2 godine ili češće ako se smatra nužnim).
English: Individuals who are CYP2D6 poor metabolisers (PM) exhibit higher mexiletine concentrations than CYP2D6 intermediate (IM), extensive (i.e. normal) or ultra-rapid (UM) metabolisers.
Croatian: Osobe koje su spori metabolizatori (engl. poor metabolisers, PM) CYP2D6, pokazuju više koncentracije meksiletina od srednjih, brzih (odnosno normalnih) ili vrlo brzih (engl. ultra-rapid, UM) metabolizatora CYP2D6.
English: What Namuscla looks like and contents of the pack Namuscla hard capsules are reddish hard gelatin capsules filled with white powder.
Croatian: Kako Namuscla izgleda i sadržaj pakiranja Tvrde kapsule lijeka Namuscla su crvenkaste tvrde želatinske kapsule s bijelim praškom.
English: Before starting treatment with Namuscla and regularly during treatment, you will have tests to check how well your heart is working,.
Croatian: Prije početka liječenja lijekom Namuscla i redovito tijekom liječenja provest ćete pretrage rada srca.
English: - liver problems - kidney problems - low or high potassium blood levels - low magnesium blood levels - epilepsy
Croatian: - probleme sa srcem - probleme s jetrom - probleme s bubrezima - snižene ili povišene razine kalija u krvi - snižene razine magnezija u krvi - epilepsiju